Stem cell transplant held off brain lymphoma longer than more chemotherapy
Original title: High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a large finished trial in people, and this treatment is already given at hospitals set up for transplants.
The short version
A stem cell transplant kept this brain cancer from coming back longer than a second round of chemotherapy, but it was harder on the body.
What was studied. Doctors compared two follow-up treatments for adults with a newly found primary CNS lymphoma, a lymphoma that starts in the brain and spinal cord. Everyone got the same starting chemotherapy first, then 229 patients were placed at random into a stem cell transplant group or a second chemotherapy group.
What they found. After 3 years, 78% of the transplant group were alive with no sign the cancer had grown. In the other chemotherapy group, that number was 51%. The transplant group also had more side effects. Five people in the transplant group died from problems after treatment, compared with two in the other group.
What this means, and what it doesn't
What it could mean: For people who are well enough to go through it, a stem cell transplant after chemotherapy may keep this cancer away longer. It is also rougher on the body. If you have this diagnosis, it is fair to ask your care team whether a transplant fits your situation.
What it doesn't mean: This is not a cure, and it is not a promise. The trial only included adults who were fit enough for a transplant and whose cancer had already responded to the first chemotherapy. It does not apply to other kinds of brain tumors. A transplant carries real risk, and some people in this trial died from it. Your own doctor still has to decide what is safe for you.
Source: PubMed, July 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.